Figure 1.
Study design.
Figure 2.
In vitro inhibition of neuroendocrine tumor cell proliferation by everolimus using MTT assay.
Figure 3.
Tumor growth of everolimus and vehicle treated human H727 xenografts in nude mice.
A significant effect of everolimus treatment was found on day 3, 7 and 10 compared with the control group. Tumor volume was found by manual drawing on the tumor boundary on CT images. N = 18 tumors/group. *) P<0.05, **) P<0.01, ***) P<0.001, treatment versus control group at same day.
Figure 4.
PET uptake in H727 xenografts.
Uptake of FDG (upper panel) and FLT (lower panel) after treatment of H727 xenografts with everolimus or vehicle. N = 8–10 tumors/group. *) P<0.05 vs. control group on same day, #) P<0.05 and ##) P<0.01 vs. baseline of same group. P-values are Bonferroni corrected.
Figure 5.
Comparison of early FLT PET on day 1 with late CT volume on day 10 in same animal. Correlations for the whole group between early PET and late CT volumes are shown in Figure 6.
Figure 6.
Early PET correlated to later tumorgrowth.
Correlations of individual tumor uptake (SUVmean) day 1 and day 3 and subsequent tumor growth until day 7 and 10. Left panel: mean uptake of FDG at day 3 correlated significantly with tumor growth until day 10, (n = 10). Right panel: mean uptake of FLT at day 1 correlated significantly with tumor growth until day 7 and FLT uptake at day 3 correlated with tumor growth until both day 7 and 10 (n = 8 tumors). Tumor growth is expressed as volume relative to baseline, 95% confidence intervals are shown. Correlations with SUVmax show same trend (not shown).